Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

Can 9 mg of mazdutide administered subcutaneously once weekly provide effective and safe body weight reduction in Chinese adults with obesity (defined as a body mass index of ≥30) compared with placebo?In 461 Chinese adults (16% had type 2 diabetes) (mean age, 34 years; mean body weight, 94 kg; mean body mass index, 34), there was a mean weight reduction of 16.65% in the mazdutide group vs 1.50% in the placebo group after 60 weeks of treatment. The most common adverse events were vomiting (53.1% in the mazdutide group vs 1.3% in the placebo group), nausea (46.9% vs 3.2%, respectively), and diarrhea (39.4% vs 6.5%).Mazdutide provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo.

Corresponding Authors: Linong Ji, MD, Department of Endocrinology and Metabolism, Peking University People’s Hospital, 11 Xizhimen South St, Beijing 100044, China (jiln@bjmu.edu.cn); Lei Qian, MD, PhD, Innovent Biologics Inc, 999 Jinguang Rd, Shanghai 201100, China (cnradium@126.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.